Next, to investigate whether canagliflozin prevented the progression of NASH to HCC by inhibiting hepatocarcinogenesis, immunohistochemical staining was performed for glutamine synthetase (GS), which is a marker of HCC. This evidence concerns the gene GLUL and metabolic dysfunction-associated steatohepatitis.